Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Dedifferentiated liposarcoma (DDLS) is a rare but aggressive cancer with high recurrence and low response rates to targeted therapies. Increasing treatment efficacy may require combinations of targeted agents that counteract the effects of multiple abnormalities. To identify a possible multicomponent therapy, we performed a combinatorial drug screen in a DDLS-derived cell line and identified cyclin-dependent kinase 4 (CDK4) and insulin-like growth factor 1 receptor (IGF1R) as synergistic drug targets. We measured the phosphorylation of multiple proteins and cell viability in response to systematic drug combinations and derived computational models of the signaling network. These models predict that the observed synergy in reducing cell viability with CDK4 and IGF1R inhibitors depends on the activity of the AKT pathway. Experiments confirmed that combined inhibition of CDK4 and IGF1R cooperatively suppresses the activation of proteins within the AKT pathway. Consistent with these findings, synergistic reductions in cell viability were also found when combining CDK4 inhibition with inhibition of either AKT or epidermal growth factor receptor (EGFR), another receptor similar to IGF1R that activates AKT. Thus, network models derived from context-specific proteomic measurements of systematically perturbed cancer cells may reveal cancer-specific signaling mechanisms and aid in the design of effective combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A combinatorial drug screen in dedifferentiated liposarcoma cell lines also identified CDK4 and IGF1R as synergistic drug targets.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [122]
In the citing paper
“The models predicted that the observed synergy of CDK4 and IGF1R inhibitors depends on activated AKT; consistent with this prediction, combined inhibition of CDK4 and IGF1R cooperatively suppressed activation of proteins within the AKT pathway (122).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“For this study, we measured synergy by the Loewe additivitybased combination index (CI) score, which can handle cases where two drugs act on targets regulating a common pathway (33) (Fig 1A).”
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“The AKT pathway is one of the major downstream pathways of IGF1R (46), and indeed we found that IGF1R inhibition with R1507 or NVP-AEW541 represses phosphorylation of AKT and downstream members of the AKT/mTOR pathway (p70S6K, S6).”
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
ZHANG, W., & LIU, H. T. (2002) · Cell Research · doi:10.1038/sj.cr.7290105 · Cited by 2,845
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Cited by
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
What is synergy? The Saariselkä agreement revisited
Tang, J., Wennerberg, K., & Aittokallio, T. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00181 · Cited by 217
Bulusu, K. C., Guha, R., Mason, D. J., Lewis, R. P. I., Muratov, E., Kalantar Motamedi, Y., Cokol, M., & Bender, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.003 · Cited by 202
Perturbation Biology: Inferring Signaling Networks in Cellular Systems
Molinelli, E. J., Korkut, A., Wang, W., Miller, M. L., Gauthier, N. P., Jing, X., Kaushik, P., He, Q., Mills, G., Solit, D. B., et al. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003290 · Cited by 187
Self-citationSimpson, A., Petnga, W., Macaulay, V. M., Weyer-Czernilofsky, U., & Bogenrieder, T. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0514-5 · Cited by 183
Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King, H., Aleksic, T., Haluska, P., & Macaulay, V. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.004 · Cited by 132
Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling
Flobak, Å., Baudot, A., Rémy, É., Thommesen, L., Thieffry, D., Kuiper, M. T. R., & Lægreid, A. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004426 · Cited by 145
DCDB 2.0: a major update of the drug combination database
Liu, Y., Wei, Q., Yu, G., Gai, W., Li, Y., & Chen, X. (2014) · Database · doi:10.1093/database/bau124 · Cited by 131
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119
“A recent drug synergy screen and network modeling study suggested that hyperactive CDK4 and IGF1R signaling also cooperate in liposarcoma (36).”
BackgroundZhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114
“Amore recent study also reported that the addition of an IGF1R inhibitor to PD0332991 led to greater inhibition of cell-cycle progression and cell metabolic activity (20).”
BackgroundKorkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Onur Sumer, S., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 100
Self-citationA Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Guenther, L. M., Dharia, N. V., Ross, L. S., Conway, A. S., Robichaud, A. L., Catlett, J. L., Wechsler, C. S., Frank, E. S., Goodale, A. B., Church, A. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0372 · Cited by 99
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 98
Systematic synergy modeling: understanding drug synergy from a systems biology perspective
Chen, D., Liu, X., Yang, Y., Yang, H., & Lu, P. (2015) · BMC Systems Biology · doi:10.1186/s12918-015-0202-y · Cited by 98
CDK4 is an essential insulin effector in adipocytes
Lagarrigue, S., Lopez-Mejia, I. C., Denechaud, P.-D., Escoté, X., Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81480 · Cited by 76
RetractedQuantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer
Jaeger, S., Igea, A., Arroyo, R., Alcalde, V., Canovas, B., Orozco, M., Nebreda, A. R., & Aloy, P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0097 · Cited by 79
He, L., Tang, J. P., Andersson, E. I., Timonen, S., Koschmieder, S., Wennerberg, K., Mustjoki, S. M., & Aittokallio, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3644 · Cited by 80
Huang, L., Jiang, Y., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/srep40752 · Cited by 84
Shin, S.-M., Kim, J.-S., Park, S.-W., Jun, S.-Y., Kweon, H.-J., Choi, D.-K., Lee, D., Cho, Y. B., & Kim, Y.-S. (2020) · Science Advances · doi:10.1126/sciadv.aay2174 · Cited by 63
Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
Garg, M., Kanojia, D., Mayakonda, A., Said, J. W., Doan, N., Chien, W., Ganesan, T. S., Chuang, L. S. H., Venkatachalam, N., Baloglu, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13485 · Cited by 70
What are the challenges with multi-targeted drug design for complex diseases?
Zięba, A., Stępnicki, P., Matosiuk, D., & Kaczor, A. A. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2072827 · Cited by 59
Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells
Tun, J. O., Salvador‐Reyes, L. A., Velarde, M. C., Saito, N., Suwanborirux, K., & Concepción, G. P. (2019) · Marine Drugs · doi:10.3390/md17090536 · Cited by 56
Haines, E., Chen, T., Kommajosyula, N., Chen, Z., Herter-Sprie, G. S., Cornell, L., Wong, K.-K., & Shapiro, G. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25803 · Cited by 51
Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma
Azuaje, F. J., Tiemann, K., & Niclou, S. P. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0098-6 · Cited by 56
Advances in computational approaches in identifying synergistic drug combinations
Sheng, Z., Sun, Y., Yin, Z., Tang, K., & Cao, Z. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx047 · Cited by 49
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
Somaiah, N., & Tap, W. D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102668 · Cited by 53
Wu, M., Sirota, M., Butte, A. J., & Chen, B. (2014) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814644730_0008 · Cited by 64
Yao, Y., Wang, Y., Chen, L., Tian, Z., Yang, G., Wang, R., Wang, C., Wu, Q., Wu, Y., Gao, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00908-0 · Cited by 47
Asano, N., Yoshida, A., Mitani, S., Kobayashi, E., Shiotani, B., Komiyama, M., Fujimoto, H., Chuman, H., Morioka, H., Matsumoto, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14652 · Cited by 47
Mason, D. J., Eastman, R. T., Lewis, R. P. I., Stott, I. P., Guha, R., & Bender, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01096 · Cited by 42
Proteomic analysis of phosphorylation in cancer
Ruprecht, B., & Lemeer, S. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.901156 · Cited by 44
Liang, R., Weigand, I., Lippert, J., Kircher, S., Altieri, B., Steinhauer, S., Hantel, C., Rost, S., Rosenwald, A., Kroiß, M., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00219 · Cited by 46
Drug antagonism and single-agent dominance result from differences in death kinetics
Richards, R., Schwartz, H. R., Honeywell, M. E., Stewart, M., Cruz‐Gordillo, P., Joyce, A. J., Landry, B. D., & Lee, M. J. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0510-4 · Cited by 42
Phosphoproteomics in translational research: a sarcoma perspective
Noujaim, J. C., Payne, L. S., Judson, I. R., Jones, R. L., & Huang, P. H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw030 · Cited by 42
Shin, S., Müller, A., Verma, N., Lev, S., & Nguyen, L. K. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006192 · Cited by 38
MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
Nair, J. S., & Schwartz, G. K. (2016) · Oncotarget · doi:10.18632/oncotarget.7335 · Cited by 36
Self-citationCassinelli, G., Pasquali, S., & Lanzi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.965261 · Cited by 34
Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations
Tang, J. P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7154-1_30 · Cited by 30
Dynamic Targeting in Cancer Treatment
Wang, Z., & Deisboeck, T. S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00096 · Cited by 31
Fan, Y., Arechederra, M., Richelme, S., Daian, F., Novello, C., Caldéraro, J., Tommaso, L. D., Morcrette, G., Rebouissou, S., Donadon, M., et al. (2017) · Hepatology · doi:10.1002/hep.29304 · Cited by 32
Delcroix, V., Mauduit, O., Tessier, N., Montillaud, A., Lesluyes, T., Ducret, T., Chibon, F., Coppenolle, F. V., Ducreux, S., & Vacher, P. (2018) · Cancers · doi:10.3390/cancers10110439 · Cited by 25
Diverse array-designed modes of combination therapies in Fangjiomics
Liu, J. H., & Wang, Z. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.125 · Cited by 23
The Art and Science of Building a Computational Model to Understand Hemostasis
Leiderman, K., Sindi, S., Monroe, D. M., Fogelson, A. L., & Neeves, K. B. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722861 · Cited by 22
Perturbation biology links temporal protein changes to drug responses in a melanoma cell line
Nyman, E., Stein, R. R., Jing, X., Wang, W., Marks, B. R., Zervantonakis, I. K., Korkut, A., Gauthier, N. P., & Sander, C. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007909 · Cited by 21
Self-citationShimizu, T., Higashijima, Y., Kanki, Y., Nakaki, R., Kawamura, T., Urade, Y., & Wada, Y. (2021) · Science Signaling · doi:10.1126/scisignal.abb3616 · Cited by 22
Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy
Yusoh, N. A., Tiley, P. R., James, S. D., Harun, S. N., Thomas, J. A., Saad, N., Hii, L., Chia, S. L., Gill, M. R., & Ahmad, H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00322 · Cited by 22
Applications of personalised signalling network models in precision oncology
Hastings, J. F., O’Donnell, Y. E. I., Fey, D., & Croucher, D. R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107555 · Cited by 19
Consequences of feedback in signal transduction for targeted therapies
Klinger, B., & Blüthgen, N. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140130 · Cited by 20
Fordham, A. M., Ekert, P. G., & Fleuren, E. D. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188613 · Cited by 17
HDACIs and TKIs combinations and their liposomal delivery for cancer treatment
Schelker, C., Nowak-Sliwinska, P. M., & Borchard, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.006 · Cited by 16
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection
Lesovaya, E. A., Fetisov, T. I., Bokhyan, B. Y., Павловна, М. В., Kulikov, E. P., Belitsky, G. A., Игоревич, К. К., & Геннадиевна, Я. М. (2024) · Cancers · doi:10.3390/cancers16020271 · Cited by 17
Chemical Biology Applied to the Study of Bacterial Pathogens
Anthouard, R., & DiRita, V. J. (2014) · Infection and Immunity · doi:10.1128/iai.02021-14 · Cited by 18
Predicting drug synergy for precision medicine using network biology and machine learning
Cüvitoğlu, A., Zhou, J., Huang, S., & Işık, Z. (2019) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720019500124 · Cited by 16
Tsirvouli, E., Touré, V., Niederdorfer, B., Vázquez, M., Flobak, Å., & Kuiper, M. T. R. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.502573 · Cited by 18
CImbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets
Flobak, Å., Vázquez, M., Lægreid, A., & Valencia, A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx161 · Cited by 16
Sharma, A., & Rani, R. (2018) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720018500178 · Cited by 16
Gilbert, A. N., Anderson, J. C., Duarte, C. W., Shevin, R. S., Langford, C. P., Singh, R., Gillespie, G. Y., & Willey, C. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-26840-4 · Cited by 15
Identification of Key Genes as Potential Drug Targets for Gastric Cancer
Hossain, M. T., Reza, M. S., Peng, Y., Feng, S., & Wei, Y. (2023) · Tsinghua Science & Technology · doi:10.26599/tst.2022.9010035 · Cited by 15
Strategies to Enhance Logic Modeling-Based Cell Line-Specific Drug Synergy Prediction
Niederdorfer, B., Touré, V., Vázquez, M., Thommesen, L., Kuiper, M. T. R., Lægreid, A., & Flobak, Å. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00862 · Cited by 15
Biochemical reaction network topology defines dose-dependent Drug–Drug interactions
Babaei, M., Evers, T. M. J., Shokri, F., Altucci, L., de Lange, E. C. M., & Mashaghi, A. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106584 · Cited by 11
Computational screen for sex-specific drug effects in a cardiac fibroblast signaling network model
Watts, K. M., Nichols, W., & Richardson, W. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-44440-9 · Cited by 10
Flobak, Å., Zobolas, J., Vázquez, M., Steigedal, T. S., Thommesen, L., Grislingås, A., Niederdorfer, B., Folkesson, E., & Kuiper, M. T. R. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1252961 · Cited by 8
The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling
Jdeed, S., Erdős, E., Bálint, B. L., & Uray, I. P. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0961 · Cited by 10
A comprehensive mechanistic model of adipocyte signaling with layers of confidence
Lövfors, W., Magnusson, R., Jönsson, C., Gustafsson, M., Olofsson, C. S., Cedersund, G., & Nyman, E. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00282-9 · Cited by 7
Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350
Simone, G. D. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1558210 · Cited by 5
Insights from Systems Biology in Physiological Studies: Learning from Context
Silva, P. H. I., Melo, D., & de Mendonça, P. O. R. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478648 · Cited by 5
Deun, K. V., Thorrez, L., van den Berg, R. A., Smilde, A. K., & Mechelen, I. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125334 · Cited by 5
Eşim, Ö., Adatepe, Ş., Sarper, M., Bakırhan, N. K., Kablan, S. E., Koçak, E., Özkan, C. K., Nemutlu, E., Savaşer, A., Özkan, S. A., et al. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105898 · Cited by 4
Chemical–Genetic Interactions as a Means to Characterize Drug Synergy
Gaikani, H. K., Giaever, G. N., & Nislow, C. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1740-3_14 · Cited by 4
Zhu, Y. T., Li, W.-M., Zhang, L., Xue, J., Zhao, M., & Yang, P. (2015) · Europe PMC (PubMed Central) · Cited by 3
Knowledge-Aware Synergistic Discovery of Drug Combinations: A Large Language Model Perspective
Lai, P.-Y., Chen, M.-S., Liao, D.-Z., Wang, C.-D., Chen, M., & Mei, L. (2025) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbbio.2025.3592471 · Cited by 3
Using Systems Pharmacology to Advance Oncology Drug Development
Kirouac, D. C. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-44534-2_19 · Cited by 2
Korkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Solit, D. B., Pratilas, C. A., et al. (2014) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/008201 · Cited by 1
Self-citationScience Signaling Podcast: 24 September 2013
Miller, M. L., Sander, C., & VanHook, A. M. (2013) · Science Signaling · doi:10.1126/scisignal.2004717
Self-citationA comprehensive dynamic model of the adipocyte
Lövfors, W. (2022) · Linköping studies in science and technology. Dissertations · doi:10.3384/9789179293130
An ML-based Cancer Genome Profile Drug Prediction Framework
Chauhan, R. S. (2018) · Türk bilgisayar ve matematik eğitimi dergisi · doi:10.17762/turcomat.v9i2.13853
Rôle du canal calcique TRPV1 dans l’ischémie-reperfusion du myocarde
Tessier, N. (2019) · theses.fr (ABES) · doi:10.70675/204cc944zcf97z409fza721z2ef60cfa4b5d
CDK4/6 inhibition induces a senescence-associated secretory phenotype via delayed NF-κB activation
Yeung, J. L.-H., Rendleman, J., Westcott, L. A., Ou, A., Pressler, M., Pagane, N., Duba, I., Hosuru, R., Tumenbayar, B., & Risca, V. I. (2026) · Life Science Alliance · doi:10.26508/lsa.202603790
BindingDB (2021) · UC San Diego · doi:10.7270/q27084pf
BindingDB (2021) · UC San Diego · doi:10.7270/q25t3pv2
Metadata
- Authors
- Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., Schwartz, G. K., & Sander, C.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Miller, Martin L.
- Molinelli, Evan J.
- Singer, Samuel
- Schwartz, Gary K.
- Sander, Chris
- ORCID
- Venue
- Science Signaling
- Published
- 2013-09-24
- Volume
- 6
- Issue
- 294
- Pages
- ra85-ra85
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- PMC
- PMC4000046
- OpenAlex
- W2129662907
- Cited by
- 86
- References
- 97
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 9 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 11 · 2017: 9 · 2016: 6 · 2015: 12 · 2014: 9 · 2013: 2
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Signaling (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32gm083937-09)
- National Cancer Institute (U54CA148967, P50CA140146, U54CA143798, P30CA008748)
- National Institute of General Medical Sciences (1T32GM083937, GM 103504, T32-GM083937, P41GM103504)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- dedifferentiated liposarcoma, CDK4, IGF-1 receptor, drug synergy, combination therapy, Akt signaling, EGFR, signaling network modeling, protein phosphorylation, cell viability, targeted therapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Computer Simulation, Drug Screening Assays, Antitumor, Drug Synergism, Humans, Liposarcoma, Models, Biological, Signal Transduction, Drug Delivery Systems, Receptor, IGF Type 1, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.